Javascript must be enabled to continue!
Regulation of Transcription Factor YAP-TEAD by Non-coding RNA LINC00857 and the Inhibitory Effects on Ovarian Cancer Cell Proliferation
View through CrossRef
This study was aimed to explore the expression and mechanism of the transcription factor YAP-TEAD
in the Hippo signaling pathway under the regulation of non-coding Ribonucleic Acid (RNA)
LINC00857 in the proliferation of ovarian cancer cells, so as to provide a scientific research basis for
clinical diagnosis and treatment of ovarian cancer. In the study, the ovarian cancer cell lines (BT 549)
were rolled into a control group (normal culture-defined as BT549/NC) and a response group
(transfected with non-coding RNA LINC00857 cultured cells-defined as BT 549YAP cells). The
expression and proliferation ability of the transcription factor YAP-TEAD in the two groups of cancer
cells were analyzed and compared. The results showed that the YAP-TEAD expression rate was the
highest in Bt549 cells; the YAP content grade (0.18) in BT 549-YAP cells was lower than BT 549/NC
(0.2) after transfection (P< 0.05); and the apoptotic rate of the response group (80%) was higher than
that of the control group (25%) after the intervention. With the extension of culture time, the expression
of CCN1 mRNA decreased (P< 0.05), and CCN2 mRNA increased (P< 0.05). After 12, 24, 36, and 48
hours, the apoptosis rate of the reaction group at different time points was higher than that of the control
group (P< 0.01). When YAP-TEAD was down-regulated, the in vitro proliferation ability of BT 549-
YAP cells was weakened compared with BT 549/NC and parental cells. It was concluded that the noncoding
RNA LINC00857 can target the transcription factor YAP-TEAD in the Hippo signaling pathway
to decrease its expression, thus inhibiting the proliferation, migration, and invasion of cancer cells, and
promoting cell apoptosis.
Title: Regulation of Transcription Factor YAP-TEAD by Non-coding RNA LINC00857
and the Inhibitory Effects on Ovarian Cancer Cell Proliferation
Description:
This study was aimed to explore the expression and mechanism of the transcription factor YAP-TEAD
in the Hippo signaling pathway under the regulation of non-coding Ribonucleic Acid (RNA)
LINC00857 in the proliferation of ovarian cancer cells, so as to provide a scientific research basis for
clinical diagnosis and treatment of ovarian cancer.
In the study, the ovarian cancer cell lines (BT 549)
were rolled into a control group (normal culture-defined as BT549/NC) and a response group
(transfected with non-coding RNA LINC00857 cultured cells-defined as BT 549YAP cells).
The
expression and proliferation ability of the transcription factor YAP-TEAD in the two groups of cancer
cells were analyzed and compared.
The results showed that the YAP-TEAD expression rate was the
highest in Bt549 cells; the YAP content grade (0.
18) in BT 549-YAP cells was lower than BT 549/NC
(0.
2) after transfection (P< 0.
05); and the apoptotic rate of the response group (80%) was higher than
that of the control group (25%) after the intervention.
With the extension of culture time, the expression
of CCN1 mRNA decreased (P< 0.
05), and CCN2 mRNA increased (P< 0.
05).
After 12, 24, 36, and 48
hours, the apoptosis rate of the reaction group at different time points was higher than that of the control
group (P< 0.
01).
When YAP-TEAD was down-regulated, the in vitro proliferation ability of BT 549-
YAP cells was weakened compared with BT 549/NC and parental cells.
It was concluded that the noncoding
RNA LINC00857 can target the transcription factor YAP-TEAD in the Hippo signaling pathway
to decrease its expression, thus inhibiting the proliferation, migration, and invasion of cancer cells, and
promoting cell apoptosis.
Related Results
Comparison of YAP/TAZ and TEAD activators on cellular models
Comparison of YAP/TAZ and TEAD activators on cellular models
Comparaison des effets de différents activateurs de YAP/TAZ et TEAD sur plusieurs modèles cellulaires
La voie Hippo (HP) consiste en une cascade de kinases qui cont...
Abstract 2693: Targeting the Hippo-YAP pathway with novel small-molecule inhibitors of the YAP-TEAD transcription activity
Abstract 2693: Targeting the Hippo-YAP pathway with novel small-molecule inhibitors of the YAP-TEAD transcription activity
Abstract
We have discovered and are developing multiple novel small molecule medicines targeting the Hippo-YAP pathway. Consisting of upstream regulatory components,...
Abstract 2200: A rational approach for discovery of inhibitors of YAP-TEAD interaction
Abstract 2200: A rational approach for discovery of inhibitors of YAP-TEAD interaction
Abstract
The Hippo signalling pathway plays a major role in organ growth regulation and tumorigenesis. By sensing contact inhibition, the central kinase network of t...
Abstract 1671: Discovery of ETS-003, a potent and selective YAP/TAZ-TEAD PPI inhibitor with broad anti-tumor activity in Hippo-YAP aberrant cancers
Abstract 1671: Discovery of ETS-003, a potent and selective YAP/TAZ-TEAD PPI inhibitor with broad anti-tumor activity in Hippo-YAP aberrant cancers
Abstract
Hippo/YAP is a conserved signaling pathway controlling organ development, tissue regeneration and immune modulation. Cascade of tumor suppressor genes (N...
Abstract LB029: Degraders of TEAD transcription factors based on interface 3 binders
Abstract LB029: Degraders of TEAD transcription factors based on interface 3 binders
Abstract
TEAD transcription factors have emerged as clinically validated targets for Hippo-altered cancers, e.g. mesothelioma driven by NF2 inactivation/deficiency. ...
Abstract A45: In silico drug discovery targeting Hippo pathway and YAP-TEAD protein-protein interactions for small-molecule anticancer agent
Abstract A45: In silico drug discovery targeting Hippo pathway and YAP-TEAD protein-protein interactions for small-molecule anticancer agent
Abstract
The Hippo pathway is one of the important pathways regulating tissue growth and proliferation. Dysregulation of this pathway can result in overgrowth of phe...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Insulin Modulates Hippo Signaling by Impairing YAP Function
Insulin Modulates Hippo Signaling by Impairing YAP Function
Yes‐associated protein (YAP) is the main transcriptional coactivator of the Hippo pathway, which regulates organ size, tissue homeostasis, and regeneration. YAP integrates multiple...

